GlobeNewswire: Genetic Technologies Ltd Contains the last 10 of 125 releaseshttp://www.globenewswire.com/External?Length=42024-03-29T13:39:09ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2024/03/26/2852301/0/en/GTG-Global-Collaborations-and-Innovation-Update.html?f=22&fvtc=4&fvtv=45300GTG Global Collaborations and Innovation Update2024-03-26T12:00:00Z<![CDATA[MELBOURNE, Australia, March 26, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in genomics-based tests in health, wellness and serious disease, is pleased to highlight a summary of the Company’s commitment to innovation. This innovation is driven by:]]>https://www.globenewswire.com/news-release/2024/03/25/2851577/0/en/GENE-to-develop-Worlds-Most-Advanced-Comprehensive-Risk-Test-Revolutionising-Personalised-Healthcare.html?f=22&fvtc=4&fvtv=45300GENE to develop Worlds Most Advanced Comprehensive Risk Test Revolutionising Personalised Healthcare2024-03-25T12:00:00Z<![CDATA[MELBOURNE, Australia, March 25, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (NASDAQ:GENE, “Company”, “GENE”), a global leader in guideline-driven genomics-based testing in health, wellness and serious diseases, is pleased to announce the development of the Company’s most advanced risk assessment test for serious diseases, building on the success of the Comprehensive Hereditary Breast and Ovarian Cancer (HBOC) test.]]>https://www.globenewswire.com/news-release/2024/02/28/2836880/0/en/GTG-to-launch-U-S-Customer-Digital-Media-Sales-Campaign.html?f=22&fvtc=4&fvtv=45300GTG to launch U.S. Customer Digital Media Sales Campaign2024-02-28T13:00:00Z<![CDATA[MELBOURNE, Australia, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (NASDAQ: GENE, “Company”, “GTG”), is pleased to announce the launch of a wide-reaching customer – targeted digital advertising campaign in the United States. This comprehensive program will drive Consumer Initiated Testing (CIT) for the company’s geneType Risk Assessment Tests. The campaign will commence end of March 2024 and will scale up throughout the remainder of the year. The U.S. wellness testing market is projected to reach $4.9 billion by 2032 from $878.9 million in 2022 with an annual growth rate of 18.86%1. GTG’s strategy ensures that the company’s geneType Risk Assessment test portfolio will be able to access this segment of this rapidly growing market in the U.S.2]]>https://www.globenewswire.com/news-release/2024/01/31/2821079/0/en/Launching-our-most-comprehensive-test-and-expanding-into-new-global-markets.html?f=22&fvtc=4&fvtv=45300Launching our most comprehensive test and expanding into new global markets2024-01-31T13:00:00Z<![CDATA[MELBOURNE, Australia, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (NASDAQ: GENE), is at the forefront in personalised predictive genomics, reshaping the healthcare landscape with its inventive strategy for early disease detection and personalized wellness is pleased to share Business update for the quarter ending 31 December 2023 (Q2 FY24).]]>https://www.globenewswire.com/news-release/2024/01/05/2804600/0/en/Genetic-Technologies-Regains-Compliance-with-Nasdaq-Minimum-Bid-Price-Requirement.html?f=22&fvtc=4&fvtv=45300Genetic Technologies Regains Compliance with Nasdaq Minimum Bid Price Requirement2024-01-05T13:00:00Z<![CDATA[MELBOURNE, Australia, Jan. 05, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (NASDAQ: GENE, “Company”) a global leader in genomics-based tests in health, wellness, and serious disease, advises that it has received formal notice from the Nasdaq Stock Market, LLC (“Nasdaq”) stating that the Company has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2). As previously disclosed, the Company received a written notice from Nasdaq on July 17, 2023, notifying the Company that it had failed to meet the $1.00 per share minimum bid price requirement for continued inclusion on the Nasdaq Capital Market.]]>https://www.globenewswire.com/news-release/2023/12/14/2796221/0/en/GeneType-s-Groundbreaking-Saliva-Test-Transforms-Early-Disease-Detection-Paving-the-Way-for-Personalized-Wellness.html?f=22&fvtc=4&fvtv=45300GeneType's Groundbreaking Saliva Test Transforms Early Disease Detection, Paving the Way for Personalized Wellness2023-12-14T13:00:00Z<![CDATA[MELBOURNE, Australia, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies (GTG) is proud to provide details of a series of recent transformative initiatives. Our commitment to advancing early detection of serious diseases through a revolutionary non-invasive saliva test has been recently showcased on several national Australian media channels. These segments highlight geneType's potential to shape the future of proactive health management.]]>https://www.globenewswire.com/news-release/2023/12/12/2794682/0/en/Genetic-Technologies-Limited-Announces-Ordinary-Share-Consolidation-and-ADS-Ratio-Change.html?f=22&fvtc=4&fvtv=45300Genetic Technologies Limited Announces Ordinary Share Consolidation and ADS Ratio Change 2023-12-12T13:00:00Z<![CDATA[MELBOURNE, Australia, Dec. 12, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in genomics-based tests in health, wellness and serious disease, announced today its plans to effect:]]>https://www.globenewswire.com/news-release/2023/10/30/2769151/0/en/Gene-Business-Update-Private-Hospital-Partnership-Expanded-Multi-Test-for-Australian-Market-and-Commercial-Partner-for-Cancer-Clinical-Trial.html?f=22&fvtc=4&fvtv=45300Gene Business Update: Private Hospital Partnership; Expanded Multi-Test for Australian Market and Commercial Partner for Cancer Clinical Trial 2023-10-30T12:00:00Z<![CDATA[MELBOURNE, Australia, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX:GTG; NASDAQ:GENE, ”Company”, “GTG”), a global leader in guideline-driven genomics-based testing in health, wellness and serious diseases, is pleased to provide an update on the company activities for the quarter ending 30 September 2023.]]>https://www.globenewswire.com/news-release/2023/10/18/2762374/0/en/GeneType-Predicting-Risk-of-Pancreatic-Cancer-Major-Breakthrough-in-Early-Detection-and-Treatment.html?f=22&fvtc=4&fvtv=45300GeneType Predicting Risk of Pancreatic Cancer: Major Breakthrough in Early Detection and Treatment2023-10-18T12:30:00Z<![CDATA[MELBOURNE, Australia, Oct. 18, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in genomics-based tests in health, wellness and serious disease, is pleased to announce the publication of a peer-reviewed research paper validating geneType’s Pancreatic Cancer risk assessment test.]]>https://www.globenewswire.com/news-release/2023/09/27/2750438/0/en/GTG-Signs-Precision-Medicine-Pilot-with-Australia-s-Largest-Private-Hospital-Network.html?f=22&fvtc=4&fvtv=45300GTG Signs Precision Medicine Pilot with Australia’s Largest Private Hospital Network2023-09-27T13:00:00Z<![CDATA[MELBOURNE, Australia, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”) – a global leader in genomics-based tests in health, wellness and serious disease is pleased to announce a partnership with the Gold Coast Private Hospital (GCPH), a member of Healthscope, to establish a Precision Medicine Clinic at the hospital.]]>Simon Morriss - Genetic Technologies Ltd CEO and Michelle Ferrari Cestari - Gold Coast Hospital Research ManagerGeneType and Gold Coast HospitalSimon Morriss, Genetic Technologies CEO's StatementGTG CEO, Simon Morriss, is pleased to announce collaboration with Gold Coast Hospital